Literature DB >> 12183332

Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.

Stephanie W Watts1, Gregory D Fink, Carrie A Northcott, James J Galligan.   

Abstract

1. Deoxycorticosterone acetate (DOCA) salt hypertension is associated with an endothelin-1 (ET-1)-dependent increase in arterial resistance and mean circulatory filling pressure. Contraction of endothelium-intact arteries and veins from sham and DOCA-salt hypertensive rats to agonists of the ET(A) (ET-1((1-31))) and ET(B) receptor (sarafotoxin 6c; S6c) was investigated in tissue baths as was expression of mRNA for ET-1 and mRNA and protein for the ET(A) and ET(B) receptor. 2. ET-1((1-31)) contracted aorta and vena cava from sham rats with a 30 fold lower potency than ET-1. Contraction was not altered by the ET(B) receptor antagonist BQ788 (100 nM) but was abolished by the ET(A) receptor antagonist ABT-627 (30 nM). 3. In DOCA-salt thoracic aorta, maximum contraction to ET-1 and ET-1((1-31)) was reduced (36.6 +/- 6.3 and 13.3 +/- 4.4% of sham response, respectively); aorta did not contract to S6c. 4. In vena cava from DOCA-salt rats, contraction to ET-1 and ET-1((1-31)) was not reduced compared to sham contraction; vena cava from sham and DOCA-salt rats contracted to S6c with a similar potency. 5. Real time RT-PCR revealed that prepro ET-1 mRNA was increased 6.6 +/- 3.3 fold and 8.7 +/- 3.9 fold greater in DOCA-salt aorta and vena cava, respectively, compared to sham. Vena cava expressed a higher content of ET(A) and ET(B) receptor mRNA than aorta (P < 0.05), but no differences were observed between sham and DOCA-salt tissues. ET(A) and ET(B) receptor protein was identified in all tissues. Immunoreactive ET(A) receptor, observed as a 65, 30 and 28 kDa bands, was expressed 400% greater in DOCA-salt aorta compared to sham, but was not altered in vena cava. Immunoreactive ET(B) receptor, observed as 120, 45 and 30 kDa bands, tended to be higher in vena cava compared to aorta, but was not different in sham and DOCA-salt vena cava. 6. These results suggest that ET(A) receptor function is impaired in aorta but not vena cava of DOCA-salt rats. The ET(B) receptor was present in the aorta but, unlike in veins, does not mediate contraction directly. A sustained response to ET-1 in the venous circulation may contribute to the elevated blood pressure in the DOCA-salt model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183332      PMCID: PMC1573459          DOI: 10.1038/sj.bjp.0704831

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Amplification of alpha adrenergic vasoconstriction in canine isolated mesenteric artery and vein.

Authors:  H Shimamoto; J P Bourreau; C Y Kwan; E E Daniel
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

2.  Endothelin ETA and ETB receptors mediate vascular smooth-muscle contraction.

Authors:  D G White; T R Cannon; H Garratt; J W Mundin; M J Sumner; I S Watts
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

3.  Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy.

Authors:  J S Li; R Larivière; E L Schiffrin
Journal:  Hypertension       Date:  1994-08       Impact factor: 10.190

4.  ETB receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation.

Authors:  H Karaki; S A Sudjarwo; M Hori; K Sakata; Y Urade; M Takai; T Okada
Journal:  Eur J Pharmacol       Date:  1993-02-16       Impact factor: 4.432

5.  Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries.

Authors:  J R Teerlink; V Breu; U Sprecher; M Clozel; J P Clozel
Journal:  Circ Res       Date:  1994-01       Impact factor: 17.367

6.  Different endothelin receptors involved in endothelin-1- and sarafotoxin S6B-induced contractions of the human isolated coronary artery.

Authors:  W A Bax; Z Aghai; C L van Tricht; C Wassenaar; P R Saxena
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

7.  Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension.

Authors:  K Fujita; Y Matsumura; S Kita; Y Miyazaki; K Hisaki; M Takaoka; S Morimoto
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

8.  Endothelin-1-induced in vitro cerebral venoconstriction is mediated by endothelin ETA receptors.

Authors:  N Fernandez; L Monge; A L Garcia-Villalon; J L Garcia; B Gomez; G Dieguez
Journal:  Eur J Pharmacol       Date:  1995-12-29       Impact factor: 4.432

9.  Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs.

Authors:  K Sato; M Oka; K Hasunuma; M Ohnishi; K Sato; S Kira
Journal:  Am J Physiol       Date:  1995-11

10.  Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein.

Authors:  S A Douglas; G R Beck; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more
  10 in total

Review 1.  The vascular endothelin system in hypertension--recent patents and discoveries.

Authors:  Meri M Hynynen; Raouf A Khalil
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-01

Review 2.  Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension.

Authors:  Raouf A Khalil
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

3.  DOCA-salt hypertension impairs artery function in rat middle cerebral artery and parenchymal arterioles.

Authors:  Nusrat Matin; Paulo W Pires; Hannah Garver; William F Jackson; Anne M Dorrance
Journal:  Microcirculation       Date:  2016-10       Impact factor: 2.628

4.  Reverse-mode Na+/Ca2+ exchange is an important mediator of venous contraction.

Authors:  Nathan R Tykocki; William F Jackson; Stephanie W Watts
Journal:  Pharmacol Res       Date:  2012-09-10       Impact factor: 7.658

Review 5.  Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.

Authors:  Marc Q Mazzuca; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

6.  A comparison of reactive oxygen species metabolism in the rat aorta and vena cava: focus on xanthine oxidase.

Authors:  Theodora Szasz; Janice M Thompson; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

7.  Endothelin (ET)-1 inhibits nicotinamide adenine dinucleotide phosphate oxidase activity in human abdominal aortic endothelial cells: a novel function of ETB1 receptors.

Authors:  Jagadeesha K Dammanahalli; Zhongjie Sun
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

8.  Pharmacological endothelin receptor interaction does not occur in veins from ET(B) receptor deficient rats.

Authors:  Keshari Thakali; James J Galligan; Gregory D Fink; Cheryl E Gariepy; Stephanie W Watts
Journal:  Vascul Pharmacol       Date:  2008-04-03       Impact factor: 5.773

9.  Divergent signaling mechanisms for venous versus arterial contraction as revealed by endothelin-1.

Authors:  Nathan R Tykocki; BinXi Wu; William F Jackson; Stephanie W Watts
Journal:  J Vasc Surg       Date:  2014-04-14       Impact factor: 4.268

10.  Big ET-1 processing into vasoactive peptides in arteries and veins.

Authors:  Stephanie W Watts; Keshari Thakali; Chuck Smark; Catherine Rondelli; Gregory D Fink
Journal:  Vascul Pharmacol       Date:  2007-09-07       Impact factor: 5.773

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.